Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT02983071Phase 2Unknown
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of lerociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by G1 Therapeutics, Inc.. Status: unknown.
02
Drugs
lerociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02983071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983071.